Botulinum Toxin in voiding Dysfunction
Peralta JP*, Godinho Ricardo, Rabaça Carlos and Sismeiro Amilcar
Department of Urology of the Portuguese Institute of Oncology of Coimbra, Portugal

Summary
A 42-year-old patient was followed in urology clinic, complaining of recurrent LUTS (lower urinary tract symptoms) after being subjected to TUIP (transurethral incision of the prostate) at 38 years of age due to bladder neck hypertrophy.

Urodynamic study was performed, and showed detrusor hypocontractility with an obstructive flow pattern and urethral hypertonicity.

He was subjected to chemical sphincterotomy with botulinum toxin type-A (BTX-A), under cystoscopic control.

After BTX-A, the patient reported improvement of the dynamic voiding pattern with frank improvement of the urodynamic parameters.

Background
This actually represents an occasional form of refractory LUTS in the young male, most of the time, after many treatments have already been preformed, and in which a recent an simple approach can lead to good practical results with improvement of QoL.

Case Presentation
A 42-year-old patient was followed in urology clinic, complaining of recurrent LUTS (lower urinary tract symptoms) after being subjected to TUIP (transurethral incision of the prostate) at 38 years of age due to bladder neck hypertrophy.

Investigations
At the time, there was no evidence of hypertrophy or tightness of the bladder neck on cystoscopy. He performed an urodynamic study (Figures 1 and 2), whose results were consistent with detrusor hypocontractility with obstructive pattern and urethral hypertonicity.

Treatment
He was subjected to chemical sphincterotomy with BTX-A injection (250U/dysport®) under cystoscopic control, at 3,6,9 and 12 o’clock at 1-1.5cm deep.

Outcome and Follow Up
After BTX-A, the patient reported an improvement of his voiding complaints, mainly bladder emptying, although he still uses abdominal effort to urinate (Figure 3). Improvement of urethral pressure profile was evidenced by perfilometry (Figure 4). The patient is currently satisfied with his clinical situation, even admitting the possibility of new chemical Sphincterotomy.

Discussion
The urethral injection of BTX-A has been demonstrated as an alternative therapy in bladder dysfunction. Through paresis of striated sphincter urethral muscle and by reducing urethral resistance, patients with incomplete urination or urinary retention are able to resume spontaneous voiding with or without abdominal effort [1-7].

Since its initial application in patients with sphincter-dyssynergia, it was demonstrated, that injection of BTX-A in striated urethral sphincter, reduces urethral pressure, residual volume, voiding pressure, detrusor contraction time and detrusor leak point pressure, thereby reducing the risk of high urinary tract injury, a factor that increases mortality and morbidity in these patients, and allowing urination without the aid of catheterization [8,9,10].

Making use of this clinical effect, it was possible to use BTX-A in bladder outlet obstruction (BOO) in various ways, including its use in patients with sphincter hypertonicity (non-relaxing urethral mecanism), as in cauda equina syndrome , peripheral neuropathy and particularly in patients with detrusor acontractility or hypocontractility, in order to promote bladder emptying with Valsalva or Credé maneuver [11,12,13].

Although the cause of refractory LUTS tends to be multifactorial, the role of the bladder neck and striated sphincter seems to be a factor to take into account, particularly in young patients with no evidence of BOO on urodynamics, or LUTS without evidence of BPH [14].
some evidence that repeating the procedure three weeks after, enhances therapeutic effect, by the cumulative effect that characterizes this drug. The potential of BTX-A in clinical practice, including urology, are a reality and an asset today.

**Learning Points/Take Home Messages**

Consider bladder neck and striated sphincter as a cause of LUTS in young patients

Urodynamic is of particular interest in this situations Botulinum toxin type A is a recent and minimally invasive approach with good results in these situations

**Copyright Statement**

I, João Pedro Amaral Peralta Lopes, The Corresponding Author, has the right to assign on behalf of all authors and does assign on behalf of all authors, a full assignment of all intellectual property rights for all content within the submitted case report and permits this case report (if accepted) to be published.

**References**

1. Leippold T, Reitz A, Schurch B (2003) Botulinum toxin as a new therapy option for voiding disorders: current state of the art. Eur Urol 44: 165-174.

2. Sloop RR, Cole BA, Escurtio RD (1997) Human response to botulinum toxin injection: type B compared with type A. Neurology 49: 189-194.

3. Coffield JA, R. VC, Simpson LL (1994) The site and mechanism of action of botulinum neurotoxin. In: Jankovic J, Hallett M, editors. Therapy with botulinum toxin. Marcel Dekker, New York, USA.

4. MacKenzie I, Burnstock G, Dolly JO (1982) The effects of purified botulinum neurotoxin type A on cholinergic, adrenergic and non adrenergic, atropine-resistant autonomic neuromuscular transmission. Neuroscience 7: 997-1006.

5. Chen JL, Chen CY, Kuo HC (2009) Botulinum toxin A injection to the bladder neck and urethra for medically refractory lower urinary tract symptoms in men without prostatic obstruction. J Formos Med Assoc 108: 950-956.

6. Kuo HC (2003) Effect of botulinum A toxin in the treatment of voiding dysfunction due to detrusor underactivity. Urology 61: 550-554.

7. Kuo HC (2003) Botulinum A toxin urethral injection for the treatment of lower urinary tract dysfunction. J Urol 170: 1908-1912.

8. McGuire EJ, Cespedes RD, O’Connell HE (1996) Leak-point pressures. Urol Clin North Am 23: 253-262.

9. Wheeler JS Jr, Walter JS, Chintam RS, Rao S (1996) Botulinum toxin injections for voiding dysfunction following SCI. J Spinal Cord Med 21: 227-229.

10. Gallien P, Robineau S, Verin M, Le Bot MP, Nicolas B, et al. (1998) Treatment of detrusor sphincter dyssynergia by transperineal injection of botulinum toxin. Arch Phys Med Rehabil 79: 715-717.

11. Phelan MW, Franks M, Somogyi GT, Yokoyama T, Fraser MO, et al. (2001) Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J Urol 165: 1107-1110.

12. Fowler CJ, Betts CD, Christmas TJ, Swash M, Fowler CG (1992) Botulinum toxin in the treatment of chronic urinary retention in women. Br J Urol 70: 387-389.

13. Kuo HC(2000) Effectiveness of periurethral botulinum toxin injection in the treatment of voiding dysfunction due to detrusor underactivity and non-relaxing urethra. Neurourol Urodyn 21:387-389.

14. Kuo HC (2007) Videourodynamics analysis of pathophysiology of men with both storage and voiding lower urinary tract symptoms. Urology 70: 272-276.

15. Kuo HC (2007) Recovery of detrusor function after urethral botulinum A toxin injection in patients with idiopathic low detrusor contractility and voiding dysfunction. Urology 69: 57-61.

16. Nitti VW, Leffkowitz G, Ficazzola M, Dixon CM (2002) Lower urinary tract symptoms in young men: videourodynamics findings and correlation with noninvasive measures. J Urol 168: 135-138.
17. Liao YM, Kuo HC (2007) Causes of failed urethral botulinum toxin A treatment for emptying failure. Urology 70: 763-766.

18. Chen SL, Bih Li, Huang YH, Tsai SJ, Lin TB, et al. (2008) Effect of single botulinum toxin A injection to the external urethral sphincter for treating detrusor external sphincter dyssynergia in spinal cord injury. J Rehabil Med 40: 744-748.